Patient-specific and dynamic evaluation of ischemic and bleeding risks is essential for optimizing dual antiplatelet therapy in patients with coronary artery disease.
Dual antiplatelet therapy has been extensively studied in the last two decades, giving opportunities for thorough evidence-based recommendations. The ESC/EACTS guidelines on DAPT in CAD provide guidance for DAPT type and duration, maintaining a patient-centred focus. Patient-specific and dynamic evaluation of the ischaemic and bleeding risks is key for optimal treatment decisions.
No takes yet. Share an insight, caveat, or question.
Costa et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: